PMV Pharmaceuticals is a company that develops small molecule therapies for p53 mutations in cancer, with their lead product candidate being PC14586 that corrects a p53 protein containing the Y220C mutation to restore the wild-type p53 function. They are also working on developing other p53 hotspot mutations and mutant p53 programs such as Wild-type p53 Induced-Phosphatase, R282W, and R273H. PMV Pharmaceuticals was previously known as PJ Pharmaceuticals and has been operational since 2013 with its headquarters located in Cranbury, New Jersey.